Blueprint Medicines Corporation BPMC
Set alert
At close · Jul 18
52-week range unavailable
- YTD
- +48.43%
- 1 year
- +13.20%
- Open
- 129.46
- Prev close
- 129.46
- Mkt cap
- 8.37B
- Vol
- 2.98M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 129.46
- High
- 129.46
- Forward P/E
- -137.72
- Beta
- 0.83
- Short ratio
- 0.62
- Inst. own
- 109.19%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 120.02
- 200-d avg
- 100.22
- 1y target
- 130.29
News
1 year ago businesswire.com
Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional…
1 year ago globenewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and…
1 year ago businesswire.com
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
1 year ago benzinga.com
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday
1 year ago globenewswire.com
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC)
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and…
1 year ago prnewswire.com
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis -- CAMBRIDGE, Mass. , June…
1 year ago benzinga.com
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.
1 year ago businesswire.com
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
1 year ago benzinga.com
This Salesforce Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
This Salesforce Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
1 year ago youtube.com
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
1 year ago zacks.com
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.
1 year ago globenewswire.com
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their…
1 year ago benzinga.com
Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday
Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday
-
1 year ago benzinga.com
This Union Pacific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
This Union Pacific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
1 year ago businesswire.com
Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. Click here to…
1 year ago businesswire.com
BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Blueprint Medicines Corporation (NASDAQ: BPMC) to Sanofi is fair to Blueprint…
1 year ago barrons.com
Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
The deal announced Monday is Sanofi's third of the year so far.
1 year ago wsj.com
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.
1 year ago globenewswire.com
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
-
1 year ago globenewswire.com
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
1 year ago globenewswire.com
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
1 year ago businesswire.com
VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery
NEW YORK--(BUSINESS WIRE)-- #AI--VantAI, a leader in generative AI and proximity-based therapeutics, announced today that it has entered into a second expansion of its collaboration and license…
1 year ago zacks.com
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.
1 year ago seekingalpha.com
Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business…
1 year ago zacks.com
Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $1.32 per share a year ago.
-
1 year ago benzinga.com
Earnings Scheduled For February 13, 2025
Earnings Scheduled For February 13, 2025
-
2 years ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
-
2 years ago benzinga.com
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
-
2 years ago benzinga.com
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.
-
2 years ago benzinga.com
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
-
2 years ago benzinga.com
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at…
-
3 years ago benzinga.com
Earnings Scheduled For October 26, 2023
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.
-
3 years ago benzinga.com
Earnings Scheduled For August 2, 2023
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimated to report quarterly earnings at $0.37 per share on revenue of $784.53 million.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
-
3 years ago benzinga.com
Earnings Scheduled For May 4, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 135 companies reached new 52-week lows.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
-
4 years ago benzinga.com
Earnings Scheduled For November 1, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.
-
4 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low…
-
4 years ago benzinga.com
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Gainers
-
4 years ago benzinga.com
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus…
-
4 years ago benzinga.com
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 1214 companies set new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 66 companies achieved new lows for the year.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
-
5 years ago benzinga.com
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.